G. Cartron

发表

6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial

C. Tournigand, M. Espié, B. Weber, 2019, The Lancet.

Early secondary acute myelogenous leukemia in breast cancer patients after treatment with mitoxantrone, cyclophosphamide, fluorouracil and radiation therapy.

G. Calais, P. Colombat, C. Linassier, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

Neutrophil role in in vivo anti-lymphoma activity of rituximab: FCGR3B-NA1/NA2 polymorphism does not influence response and survival after rituximab treatment.

P. Colombat, M. Ohresser, Hervé Watier, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.